Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is for patients with newly diagnosed glioblastoma, as well as patients who have
recurring glioblastoma. Subjects will be given daily paxalisib and metformin while also
maintaining a ketogenic diet.
The purpose of this study is to assess the safety of Paxalisib while maintaining a ketogenic
diet (a high fat, low carbohydrate diet) and Metformin (a drug approved by the Food and Drug
Administration to treat type 2 diabetes), and to see what effects it has on glioblastoma.